Ivy Lane Capital Management’s Quest Diagnostics DGX Stock Holding History

Ivy Lane Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.36M	Buy	30,000 +1,000	+3%	+$196K	9.21%	4
2026 Q1	$5.68M	Hold	29,000	–	–	8.59%	5
2025 Q4	$5.03M	Hold	29,000	–	–	6.36%	5
2025 Q3	$5.53M	Sell	29,000 -21,000	-42%	-$3.73M	6.18%	7
2025 Q2	$8.98M	Sell	50,000 -7,000	-12%	-$1.22M	4.95%	7
2025 Q1	$9.64M	Hold	57,000	–	–	5.81%	6
2024 Q4	$8.6M	Hold	57,000	–	–	4.64%	10
2024 Q3	$8.85M	Buy	57,000 +10,000	+21%	+$1.49M	5%	8
2024 Q2	$6.43M	Buy	47,000 +7,000	+18%	+$959K	3.74%	9
2024 Q1	$5.32M	Buy	+40,000	New	+$5.19M	3.26%	11

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Ivy Lane Capital Management's DGX Position: Q2 2026 in Review

Ivy Lane Capital Management increased its Quest Diagnostics (DGX) stake by 3.4% in Q2 2026, buying an estimated $196K and bringing the position to 30,000 shares worth $6.36M. The position accounts for 9.21% of the portfolio, ranked #4.

Ivy Lane Capital Management first reported a position in DGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.64M in Q1 2025. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Ivy Lane Capital Management held 30,000 shares of Quest Diagnostics worth $6.36M as of Q2 2026.
Ivy Lane Capital Management bought 1,000 Quest Diagnostics shares in Q2 2026, an estimated $196K.
Quest Diagnostics made up 9.21% of Ivy Lane Capital Management's portfolio in Q2 2026, its #4 holding.
Ivy Lane Capital Management first reported a position in Quest Diagnostics in Q1 2024 and has held it in 10 quarters since.
Ivy Lane Capital Management's Quest Diagnostics position peaked at $9.64M in Q1 2025.
1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Ivy Lane Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.